Basic Information

Gene symbol CTAG1B Synonyms CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 Type of gene protein-coding
Description cancer/testis antigen 1B

GTO ID GTC0115
Trial ID NCT01352286
Disease Multiple Myeloma
Altered gene NY-ESO-1
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment NY-ESO-1 TCR-T cells
HLAHLA-A*02:01
PhasePhase2
Recruitment statusCompleted
TitleA Phase I/IIa, Dual-cohort, Two-site, Clinical Trial Evaluating the Safety and Activity of Redirected Autologous T Cells Expressing a High Affinity TCR Specific for NY-ESO-1 Administered Post ASCT in Patients With Advanced Myeloma
Year2011
CountryUnited States
Company sponsorGlaxoSmithKline
Other ID(s)209393|ADP 01411
Vector information
Vectorlentivirus
ConstructNY-ESO-1c259T cells
Transgene/Inserted geneCTAG1B
Regulatory elementEF1α promoter; a Woodchuck hepatitis virus post-translational regulatory element (WPRE)

Clinical Result

Cohort 1
Administration route infusion
Dosage 2.4E9 cells (average)
Donor type autologous
Pts 25
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 3/25(CR); 18/25(PR)
Adverse reactions 14/25(All-cause mortality); 17/25(Blood and lymphatic system disorders; Cardiac disorders; Gastrointestinal disorders; General disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified, incl cysts and polyps; Nervous system disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders)
References PMID: 26193344

Relationship Graph

Overview of Knowledge Graph